Grindeks traces its roots back to 1946. It is headquartered in Riga and operates across multiple countries via its group subsidiaries. The company produces original branded medicines, generic products, and active pharmaceutical ingredients (APIs), and supplies these to more than 100 countries worldwide.

Originally focused on its own brand portfolio, Grindeks has now re-oriented to offer contract manufacturing and out-licensing services — making use of unused capacity in its manufacturing sites in Latvia, Estonia and Slovakia.

The company serves a broad range of therapeutic needs including cardiovascular, central nervous system, oncology, diabetes, dermatology, and other areas.

Grindeks combines internal research and development, manufacturing, quality control, regulatory compliance, and global sales & distribution — offering a full lifecycle solution for pharmaceutical products.

Key Products and Services

• Original branded medicines — including proprietary products developed and sold under the “Grindeks” name.
• Generic medicines — a wide range of generic formulations across multiple therapeutic areas.
• Active Pharmaceutical Ingredients (APIs) — production of APIs that supply both internal and external clients.
• Contract Development & Manufacturing (CDMO) services — development, analytical studies, formulation, and full GMP manufacturing for third-party clients. Recent strategic shift to offer external collaborations utilising underused plant capacity.
• Out-licensing and ready-to-file dossiers / regulatory packages — helping partners with marketing authorisation submissions, especially for EU and international markets.

Grindeks combines decades of heritage in pharmaceutical manufacturing with modern flexibility — now offering a complete CDMO and out-licensing platform while maintaining a broad product portfolio. With production sites across Latvia, Estonia and Slovakia and a global export footprint, the company is well positioned to support both internal and external partners across development, manufacturing, and regulatory pathways worldwide.